IMVT

Immunovant Inc

28.41

Oct 23 • 3:59 PM ET -0.69 (-2.37%)

28.03

Aftermarket • 7:30 PM ET -0.38 (-1.34%)

Healthcare Biotechnology USA Mid NASD

Peers: ARGX VRDN DNTH ROIV SYRE VERA JNJ KYTX CABA AMGN

| Held by: VTI VB XBI IWM VBK VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	5.87B
Enterprise Value	5.07B
Income	-538.22M
Sales	0.00M
Book/sh	3.57
Cash/sh	3.86
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	315
IPO	Jun 21, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.97
P/C	7.36
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.27
Current Ratio	7.27
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.81
EPS next Y	-2.92
EPS next Q	-0.74
EPS this Y	-6.00%
EPS next Y	0.58%
EPS next 5Y	12.21%
EPS past 3/5Y	-17.37% -17.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	1.28%
Sales Y/Y TTM	-
EPS Q/Q	-5.60%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-19.26% -

Insider Own	58.93%
Insider Trans	-0.32%
Inst Own	52.25%
Inst Trans	0.43%
ROA	-71.10%
ROE	-80.10%
ROIC	-73.19%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.63%
SMA50	-21.16%
SMA200	-11.15%
Trades

Shs Outstand	206.26M
Shs Float	84.83M
Short Float	20.53%
Short Ratio	13.10
Short Interest	17.42M
52W High	45.42 -37.45%
52W Low	18.51 53.48%
Volatility	4.27% 4.00%
ATR (14)	1.29
RSI (14)	31.89
Beta	0.93
Rel Volume	0.48
Avg Volume	1.33M
Volume	641,438

Perf Week	6.29%
Perf Month	-16.44%
Perf Quarter	-29.13%
Perf Half Y	-0.59%
Perf YTD	11.76%
Perf Year	51.60%
Perf 3Y	-15.95%
Perf 5Y	242.29%
Perf 10Y	-
Recom	1.47
Target Price	48.88
Prev Close	29.10
Price	28.41
Change %	-2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Bernstein	Mkt Perform	$28
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Oct-14-25	Initiated	Truist	Hold	$16
Jul-10-25	Resumed	Goldman	Neutral	$18
Mar-03-25	Initiated	Jefferies	Hold	$20
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform	$36
Oct-09-24	Reiterated	Oppenheimer	Outperform	$47 → $53
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30

Show Previous Ratings

Oct-21-26 07:00AM	Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire)
Oct-08-26 01:33PM	IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class (Stocktwits) -5.56%
Sep-24-26 10:14AM	Lillys latest China drug deal; Immunovants setback in lupus (BioPharma Dive)
05:32AM	Roivant reports top-line data from IMVT-1402 CLE trial (Clinical Trials Arena)
Sep-23-26 08:32AM	Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal IMVT Stock Heads For Over 3-Month Lows (Stocktwits) -7.37%
08:12AM	Loading…
08:12AM	Roivants Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss (InvestorsHub)
08:10AM	Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint (InvestorsHub)
07:00AM	Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus (GlobeNewswire)
Aug-06-26 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
Jul-23-26 04:05PM	Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 (GlobeNewswire)
May-20-26 01:20PM	Can a New Arthritis Drug Make Immunovant the Next Biotech Star? (Barrons.com) +35.26%
11:38AM	2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug (Barrons.com)
09:50AM	Why These Two Biotech Stocks Just Rocketed, As One Prepares To Break Out (Investor's Business Daily)
09:15AM	Immunovant Stock Surges 22% on Trial Data. Earnings Are an Afterthought. (Barrons.com)
08:49AM	Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT) (InvestorsHub)
07:00AM	Loading…
07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 (GlobeNewswire)
May-11-26 04:05PM	Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 (GlobeNewswire)
Apr-02-26 08:20AM	Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM (BioPharma Dive)
07:00AM	Immunovant shares plunge after phase 3 trials fails to meet primary endpoint (Investing.com)
05:00AM	Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
Mar-05-26 12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
Mar-04-26 02:30AM	Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update (Insider Monkey)
Feb-19-26 09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 10:10AM	Immunovant Q3 Earnings Call Highlights (MarketBeat) +12.43%
07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
Feb-02-26 09:55AM	Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
05:25PM	Loading…
Jan-23-26 05:25PM	Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-15-26 09:55AM	How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% (Zacks)
Jan-12-26 10:11AM	Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling (Insider Monkey)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-15-25 04:28PM	Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse (Investor's Business Daily)
Dec-11-25 01:29AM	Immunovant Announces Pricing of $550 Million Common Stock Financing (GlobeNewswire) +5.31%
Dec-10-25 11:30AM	Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Nov-29-25 01:29PM	Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings (Insider Monkey)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 (GlobeNewswire)
Oct-31-25 10:03AM	Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results (Insider Monkey)
Oct-27-25 04:10PM	Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire) +13.15%
Oct-08-25 12:57AM	JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 (Insider Monkey)
Sep-30-25 04:00AM	Where is Immunovant (IMVT) Heading According to Analysts? (Insider Monkey)
Sep-10-25 11:30AM	Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 06:17PM	Why Immunovant Stock Blasted Higher Today (Motley Fool) +10.82%
12:57PM	Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-12-25 10:26AM	Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-11-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-16-25 12:00PM	All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy (Zacks)
09:55AM	Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? (Zacks)
09:38AM	Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating (Insider Monkey)
Jul-06-25 04:15AM	LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT (Insider Monkey)
Jun-02-25 12:00PM	Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 (GlobeNewswire) +5.60%
May-09-25 09:02AM	Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? (Insider Monkey)
Apr-22-25 06:00AM	Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax (BioPharma Dive)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-08-25 10:05AM	Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? (Insider Monkey) -7.51%
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
Mar-21-25 12:17PM	Immunovant price target raised to $61 from $58 at Stifel (TipRanks)
Mar-20-25 12:30PM	Immunovants batoclimab shows impressive efficacy in MG, says H.C. Wainwright (TipRanks)
10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
01:12PM	Immunovant will not seek approval for MG therapy, despite hitting endpoints (Clinical Trials Arena)
12:39PM	Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data (Benzinga)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Immunovant claims study success for immune disease drug but holds off on submission (BioPharma Dive)
07:45AM	Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire) -6.14%
Mar-05-25 07:13PM	Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.03%
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Feb-23-25 01:33PM	Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-22-25 12:53AM	Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? (Insider Monkey)
Feb-19-25 04:49PM	Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
09:35AM	Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-10-25 11:57PM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 06:30AM	Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 (GlobeNewswire) -9.55%
Jan-30-25 05:03PM	Heres Why Immunovant, Inc. (IMVT) Will Double in 2025 (Insider Monkey)
Jan-17-25 11:10AM	Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-16-25 08:45AM	Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each (GuruFocus.com)
Jan-13-25 08:00AM	Immunovant Announces $450 Million Private Placement (GlobeNewswire)
Dec-20-24 07:20AM	Immunovant price target lowered to $45 from $47 at Wells Fargo (TipRanks)
Nov-21-24 05:31PM	Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-13-24 03:05AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 06:30AM	Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-29-24 06:30AM	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting (GlobeNewswire)
Oct-01-24 09:58AM	Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip? (Insider Monkey)
Sep-30-24 11:12AM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? (Insider Monkey)
Sep-09-24 12:54PM	What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? (Benzinga) -7.61%
09:13AM	Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses (Pharmaceutical Technology)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stout Jay S	Chief Technology Officer	Oct 21 '26	Sale	28.94	2,595	75,099	198,937	Oct 23 04:55 PM
Stout Jay S	Chief Technology Officer	Oct 07 '26	Sale	32.06	3,809	122,117	201,532	Oct 09 05:05 PM
Van Tuyl Christopher	Chief Legal Officer	Oct 07 '26	Sale	32.06	1,327	42,544	175,218	Oct 09 05:05 PM
Gloria Melanie	Chief Operating Officer	Oct 07 '26	Sale	32.06	2,241	71,846	217,060	Oct 09 05:04 PM
Venker Eric	Chief Executive Officer	Oct 01 '26	Option Exercise	14.46	92,187	1,333,024	346,467	Oct 05 07:42 PM
Venker Eric	Chief Executive Officer	Oct 02 '26	Sale	34.11	3,506	119,590	257,075	Oct 05 07:42 PM
Van Tuyl Christopher	Chief Legal Officer	Sep 23 '26	Sale	36.36	2,846	103,481	176,545	Sep 25 04:05 PM
Pande Atul	Director	Aug 28 '26	Option Exercise	8.43	1,500	12,645	118,231	Aug 28 04:27 PM
Pande Atul	Director	Aug 28 '26	Sale	43.27	1,500	64,905	116,731	Aug 28 04:27 PM
Gloria Melanie	Chief Operating Officer	Aug 20 '26	Sale	44.16	3,056	134,953	219,301	Aug 21 04:03 PM
Pande Atul	Director	Jul 24 '26	Option Exercise	8.43	1,500	12,645	118,231	Jul 24 05:59 PM
Pande Atul	Director	Jul 24 '26	Sale	39.80	1,500	59,700	116,731	Jul 24 05:59 PM
Girao Tiago	Chief Financial Officer	Jul 23 '26	Sale	38.69	6,798	263,015	240,798	Jul 24 05:57 PM
Stout Jay S	Chief Technology Officer	Jul 23 '26	Sale	38.69	2,857	110,537	205,341	Jul 24 05:57 PM
Gloria Melanie	Chief Operating Officer	Jul 08 '26	Sale	39.55	2,036	80,532	222,357	Jul 10 04:15 PM
Van Tuyl Christopher	Chief Legal Officer	Jul 08 '26	Sale	39.55	1,206	47,702	179,391	Jul 10 04:13 PM
Stout Jay S	Chief Technology Officer	Jul 08 '26	Sale	39.55	3,487	137,925	208,198	Jul 10 04:12 PM
Venker Eric	Chief Executive Officer	Jul 01 '26	Option Exercise	14.46	92,188	1,333,038	344,001	Jul 06 05:01 PM
Venker Eric	Chief Executive Officer	Jul 02 '26	Sale	38.48	3,092	118,980	254,280	Jul 06 05:01 PM
Gloria Melanie	Chief Operating Officer	Jun 26 '26	Sale	38.31	17,714	678,604	224,393	Jun 26 07:46 PM
Stout Jay S	Chief Technology Officer	Jun 26 '26	Sale	38.31	40,000	1,532,309	211,685	Jun 26 07:45 PM
Van Tuyl Christopher	Chief Legal Officer	Jun 26 '26	Option Exercise	15.20	17,824	270,925	198,421	Jun 26 07:45 PM
Van Tuyl Christopher	Chief Legal Officer	Jun 26 '26	Sale	38.31	17,824	682,887	180,597	Jun 26 07:45 PM
Girao Tiago	Chief Financial Officer	Jun 26 '26	Option Exercise	15.90	10,000	159,000	257,596	Jun 26 07:44 PM
Girao Tiago	Chief Financial Officer	Jun 26 '26	Sale	38.46	10,000	384,600	247,596	Jun 26 07:44 PM
Pande Atul	Director	Jun 26 '26	Option Exercise	8.43	1,500	12,645	118,231	Jun 26 07:43 PM
Pande Atul	Director	Jun 26 '26	Sale	38.01	1,500	57,015	116,731	Jun 26 07:43 PM
JAY S STOUT	Officer	Jun 26 '26	Proposed Sale	38.30	40,000	1,532,196		Jun 26 04:25 PM
CHRIS ADAIR VAN TUYL	Officer	Jun 26 '26	Proposed Sale	38.31	17,824	682,800		Jun 26 04:22 PM
MELANIE GLORIA	Officer	Jun 26 '26	Proposed Sale	38.31	17,714	678,552		Jun 26 04:20 PM
TIAGO GIRAO	Officer	Jun 26 '26	Proposed Sale	38.46	10,000	384,640		Jun 26 04:18 PM
Van Tuyl Christopher	Chief Legal Officer	Jun 18 '26	Sale	35.39	2,634	93,217	180,597	Jun 22 04:02 PM
Pande Atul	Director	Jun 15 '26	Option Exercise	8.43	1,500	12,645	118,231	Jun 16 04:03 PM
Pande Atul	Director	Jun 15 '26	Sale	34.02	1,500	51,030	116,731	Jun 16 04:03 PM
Atul Pande	Director	Jun 15 '26	Proposed Sale	33.62	6,000	201,720		Jun 15 04:35 PM
Fromkin Andrew J.	Director	May 28 '26	Option Exercise	8.22	196,601	1,615,328	296,333	May 29 04:04 PM
Fromkin Andrew J.	Director	May 28 '26	Sale	33.51	221,951	7,438,111	74,382	May 29 04:04 PM
ANDREW J FROMKIN	Director	May 28 '26	Proposed Sale	33.52	221,951	7,438,710		May 28 04:12 PM
Gloria Melanie	Chief Operating Officer	May 20 '26	Sale	32.45	3,115	101,072	242,107	May 22 04:03 PM
Pande Atul	Director	May 20 '26	Option Exercise	8.43	6,000	50,580	122,731	May 20 09:22 PM
Pande Atul	Director	May 20 '26	Sale	32.00	6,000	192,000	116,731	May 20 09:22 PM
Atul Pande	Director	May 20 '26	Proposed Sale	26.29	6,000	157,740		May 20 04:37 PM
Susman Robert Graham	Director	May 01 '26	Sale	27.17	2,502	67,979	36,394	May 01 06:40 PM
ROBERT G SUSMAN	Director	May 01 '26	Proposed Sale	27.14	2,502	67,917		May 01 04:46 PM
Girao Tiago	Chief Financial Officer	Apr 23 '26	Sale	29.62	25,760	763,011	247,596	Apr 24 04:07 PM
Stout Jay S	Chief Technology Officer	Apr 23 '26	Sale	29.62	2,754	81,573	251,685	Apr 24 04:05 PM
Van Tuyl Christopher	Chief Legal Officer	Apr 08 '26	Sale	24.83	5,165	128,247	183,231	Apr 10 04:05 PM
Gloria Melanie	Chief Operating Officer	Apr 08 '26	Sale	24.83	8,722	216,567	245,222	Apr 10 04:03 PM
Stout Jay S	Chief Technology Officer	Apr 08 '26	Sale	24.83	10,132	251,578	254,439	Apr 10 04:02 PM
Venker Eric	Chief Executive Officer	Apr 01 '26	Option Exercise	14.46	368,750	5,332,125	368,750	Apr 03 04:33 PM
Venker Eric	Chief Executive Officer	Apr 02 '26	Sale	24.10	14,229	342,854	19,561	Apr 03 04:33 PM
Van Tuyl Christopher	Chief Legal Officer	Mar 18 '26	Sale	24.97	2,877	71,839	147,053	Mar 20 04:11 PM
Gloria Melanie	Chief Operating Officer	Feb 25 '26	Sale	27.85	3,238	90,184	170,273	Feb 27 04:07 PM
MICHAEL GEFFNER	Officer	Feb 10 '26	Proposed Sale	26.77	5,800	155,237		Feb 10 05:16 PM
Stout Jay S	Chief Technology Officer	Jan 21 '26	Sale	26.03	1,977	51,461	197,634	Jan 23 04:21 PM
Stout Jay S	Chief Technology Officer	Jan 07 '26	Sale	26.53	1,203	31,914	199,611	Jan 09 04:03 PM
Van Tuyl Christopher	Chief Legal Officer	Dec 18 '25	Sale	26.91	10,813	290,943	149,930	Dec 19 04:05 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Fromkin Andrew J.	Director	Dec 01 '25	Sale	23.25	22,249	517,189	85,852	Dec 03 06:14 PM
Hughes Douglas J.	Director	Dec 01 '25	Sale	23.24	15,000	348,665	120,773	Dec 03 06:14 PM
ANDREW J FROMKIN	Director	Dec 01 '25	Proposed Sale	24.15	22,249	537,313		Dec 01 04:35 PM
DOUGLAS HUGHES	Director	Dec 01 '25	Proposed Sale	24.15	15,000	362,250		Dec 01 04:34 PM
MICHAEL GEFFNER	Officer	Nov 26 '25	Proposed Sale	23.70	50,000	1,185,045		Nov 26 05:07 PM
MICHAEL GEFFNER	Officer	Nov 25 '25	Proposed Sale	23.38	103,897	2,428,804		Nov 25 07:16 PM
Gloria Melanie	Chief Operating Officer	Nov 20 '25	Sale	23.62	12,626	298,237	173,511	Nov 21 04:24 PM

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.

M.D.Dr. Frank M. Torti M.B.A.

Pharm.D.Dr. Eric Venker M.D.

Chief Financial OfficerMr. Tiago M. Girao CPA

Chief Operating OfficerMs. Melanie Gloria B.S.N.

Ph.D.Dr. Jay S. Stout M.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMVT

Immunovant Inc

Upgrade your Finviz experience